WO2024028782 - NLRP3 INFLAMMASOME INHIBITORS
National phase entry is expected:
Publication Number
WO/2024/028782
Publication Date
08.02.2024
International Application No.
PCT/IB2023/057819
International Filing Date
02.08.2023
Title **
[English]
NLRP3 INFLAMMASOME INHIBITORS
[French]
INHIBITEURS DE L'INFLAMMASOME NLRP3
Applicants **
NOVARTIS AG
Lichtstrasse 35
4056 Basel, CH
Inventors
GE, Xiaobin
Suzhou Novartis Technical Development Co., Ltd.
18-1 Tonglian Road Bixi subdistrict Changshu
Jiangsu, CN
MATTES, Henri
958 quartier le Cadeton
83570 Monfort sur Argens, FR
SHI, Zhicong
China Novartis Institutes for Biomedical Research Co., Ltd.
4218 Jinke Road, Pudong New Area
Shanghai, CN
XIA, Mei
China Novartis Institutes for Biomedical Research Co., Ltd.
4218 Jinke Road, Pudong New Area
Shanghai, CN
YE, Ning
Suzhou Novartis Technical Development Co., Ltd.
18-1 Tonglian Road Bixi subdistrict Changshu
Jiangsu, CN
Priority Data
63/370,300
03.08.2022
US
PCT/CN2023/097282
30.05.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1670 | |
| EPO | Filing, Examination | 6433 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 3910 |
Total: 13210 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.[French]
sont tels que définis dans la description, qui inhibent l'activité de l'inflammasome de la protéine 3 du récepteur de type NOD (NLRP3). L'invention concerne en outre les procédés pour leur préparation, des compositions pharmaceutiques et des médicaments les contenant, et leur utilisation dans le traitement de maladies et de troubles médiés par NLRP3.